Monday, September 06, 2021

Case Study - PLUS Study and The George Institute for Global Health



When it comes to clinical trials, we look to make a difference around the world with our savvy software platform. We speak to Sharon Micallef, a Senior Project Manager from The George Institute for Global Health, about her experience working with the team at Spiral to produce a database for her latest study.

~

With 20 years of experience behind her as a nurse and an intensive care research coordinator, Sharon Micallef understands the demands and pressures of working within a hospital environment. Now a senior project manager at The George Institute for Global Health, a leading independent medical research institute, she has spent the last ten years working in the Critical Care Division on academically-based studies, drawing on her previous experience to help run trials that will benefit critically ill patients.    

Based in Sydney, her latest study, PLUS (Plasma-Lyte® Vs Saline) is a multi-centre, blinded, randomised, controlled trial (RCT) which will determine whether fluid resuscitation and intravenous fluid therapy with a “balanced” crystalloid solution (Plasma-Lyte 148®) decreases 90-day mortality in critically ill patients requiring fluid resuscitation when compared with the same treatment using 0.9% sodium chloride (saline).

Essentially, the study has been comparing two types of intravenous fluids that are used as standard care in ICUs in Australia and New Zealand. There has been an ongoing discussion about the high chloride content in saline and its potential to cause acute kidney injury, but they wanted to know, is Plasma-Lyte safer? Sharon’s study needed to easily and efficiently compare these two standard fluids for patients that require fluid resuscitation in ICUs.

With over 5,000 patients enrolled across Australia and New Zealand, it was vital to create a study database that was designed in a way that made inputting information on the frontline as easy as possible. Halfway through the initial study database design, Sharon came to the realisation that it was too complicated from a research coordinator’s perspective. 

“If your research coordinators find it hard to work with the database, it impacts on the study, recruitment, speed of entering data - the flow-on effect is huge”

Knowing that the current format would slow down recruitment, Sharon decided that something needed to change - and fast. Having worked with Spiral before on the HEAT study several years ago, Sharon felt that engaging with our team would be the right way to go, even if it meant a setback in the timelines of the study. 

A conversation with the PLUS study Chief Investigator Professor Simon Finfer led to a meeting with our Founder Audrey, and work got underway almost immediately and - as they say - the rest is history. This change in the database meant an 8-month delay in starting recruitment but Sharon believes it was worth the wait. 

“I tell everyone it is worth putting that effort in at the beginning. In the end, we haven’t needed the data validation resources other studies require because it was so beautifully done by Spinnaker - I’m very grateful to Audrey and the team - we have a great working relationship”

The bespoke design process was something new to Sharon and she admits being thrown in the deep end. Sharon provided paper forms to work from (randomisation, baseline etc). Our team were then able to design a similar electronic format. 

“There was a lot of hard work involved but Audrey and the team were extremely patient with me”

With her own personal experience front of mind, Sharon understood the wants and needs of both ICU nurses and research coordinators and was able to translate this to Spiral. It was imperative that the functioning database required very few steps, making the randomisation process as easy as possible for the nursing and medical staff who were physically inputting the information while attending to a critically ill patient. This need underpinned the entire trial. 

“Throughout the process, I would think to myself: what would I want if I was working at the other end? What would make my work easier?”

While the results of Sharon’s study are still embargoed, she could say that working with Spiral and the use of Spinnaker has made the process so much easier. Being able to access reports and blinded data all the way through the study has made things so much more efficient.

To give some background on this, study databases traditionally work with something of a data management ‘middle man’. Meaning that if a report is needed, it has to be requested through data management, taking a few days to return before anyone can review the data and check for inconsistencies. But with the use of Spinnaker, if Sharon needs a report with specific data, she can simply download a blinded report,  filter data, check for inconsistencies and send data queries to sites straight away. Sharon believes the ease with which she is able to access and review everything herself saves so much time. 

“It is undoubtedly one of the best features.”

When looking to the future of trials, Sharon believes that a good database is absolutely essential. Without one, timelines can stretch out endlessly, making the trial seem impossible to complete. Whilst Sharon has mostly worked on randomised controlled trials, she loves the way that Spiral has been able to embrace platform trials where multiple treatments are tested at the one time.

Personally driven by the power of clinical research, Sharon is an advocate for any product that enables researchers to conduct trials more efficiently, which in turn benefits people and patients in the long run. Her inherent need to help people through her study, research and trials is made all that much easier with Spiral. 


“Spiral has been amazing, I have had a great time working with them. They have been very professional and answered all my questions, even the silly ones. I have learnt a lot from Audrey and the team. I would highly recommend them as a company and their product to anyone really. It makes my job a lot easier.”

Friday, August 06, 2021

Full-dose blood thinners benefit moderately ill COVID-19 patients

REMAP-CAP, an application in Spiral’s study manifest, has recently been used in a collaborative clinical trial that focused on identifying effective treatments for critically ill Covid-19 patients.
tment options.

Thrombosis was considered to contribute to morbidity and mortality in Covid-19. It was hypothesized that therapeutic anticoagulation would improve outcomes in critically ill patients with Covid-19.

An open-label, adaptive, multiplatform, randomized, clinical trial was conducted. Patients with severe Covid-19, defined as the requirement for organ support with high flow nasal cannula, non-invasive ventilation, invasive ventilation, vasopressors, or inotropes, were randomized to receive therapeutic anticoagulation with heparin or pharmacological thromboprophylaxis as per local usual care.

Trial data analysis involved 1,074 critically ill and 2,219 moderately ill patients. Physician investigators gauged how long participants were free of organ support up to 21 days after enrolling in the clinical trial. The investigators discovered that in moderately ill patients full-dose heparin reduced the need for organ support compared to those who received lower-dose heparin. By contrast, for critically ill patients, full-dose heparin was associated with a high probability of a worse outcome.

The worldwide multi-platform trial spanned five continents in over 300 hospitals to urgently test blood thinners on both sets of patients, the critically and non-critically ill.

The results have shown that full-dose anticoagulation with the blood thinner heparin improves survival outcomes and reduces the need for vital organ support such as mechanical ventilation in moderately ill COVID-19 patients, but does not yield the same positive outcomes among critically ill patients already requiring life support.

As summarised by Professor Steve Webb, director of REMAP-CAP: “Our conclusions have set a new, accessible and affordable standard of care for moderately ill hospitalised COVID-19 patients around the world using a familiar drug. As such the results of the trial can be immediately applied,”

These results come at a crucial time when Australia is dealing with outbreaks in several states, therefore there is renewed interest in treatment options.

Spiral is proud to be a part of this worldwide multi-platform trial, one that spanned five continents in over 300 hospitals, helping to urgently test blood thinners on both sets of patients who were ill or critically ill with Covid-19.

Dive deeper:

The REMAP-CAP Website


Thursday, August 05, 2021

Meet Emma - One of our Project Managers at Spiral




Meet Emma. As a Project Manager, Emma wears many hats here at Spiral. Her main role is to oversee the software development used in clinical trials all around the world, but on any given day you can find her jumping from testing to managing sprints, answering support tickets, developing wireframes or liaising with clients on Zoom.

 “It is an incredibly agile environment. Whatever comes my way - I jump on it and deal with it”

When Emma left school, she thought a career in tourism would be her calling. She completed her degree but a casual job at a pet store led to seven years as a vet nurse. As an animal lover, it was the space Emma thought she would be in for the rest of her career but she found that some aspects of the job took a huge emotional toll on her.  

Deciding it was time to leave this role behind, her career went down a different path as she took the plunge into IT. Having no previous experience she managed to get her foot in the door of a large corporation. Emma found she excelled within this industry - it even took her to Silicon Valley where she and her husband worked within a Kiwi-owned IT company.

Upon her return to New Zealand, Emma took up a senior role at an HR Technology SaaS company. This role lasted for six years until Covid struck, causing her job to be made redundant. Despite this, Emma enjoyed success with several contract roles following her redundancy. When looking for the next step in her career, she came across an advert for a Project Manager at Spiral and couldn't believe what she was reading. The company was doing things she could be passionate about and be rewarded in facilitating.

“I thought, what is the catch? This is too good to be true”

Now living in Tauranga and working remotely for Spiral, Emma wonders why she hadn’t got into this space earlier. She loves the flexibility of working remotely with the support of her colleagues. She compares it to her past experience in open-plan offices where it was easy to get interrupted or feel like she could never fully complete a job to her satisfaction.

“I love working from home. Corporates that are trying to maintain the traditional office environment haven’t given remote working much of a chance to see how well their employees can perform.”

Looking back Emma realises just how valuable her experience has been to get her to where she is today. Two very unlikely industries have collided to provide her with the skill sets that she uses every single day at Spiral. She owes her medical knowledge, understanding of the jargon, and even pronunciation of certain medicines to her vet nurse experience. On the other hand, her years within the IT industry have given her the valuable background to oversee the software development at Spiral. 

“My job history has come together and manifested in a role that I never knew was possible.” 

When reflecting on the challenges of the role, Emma admits there are stressors involved. The juggling can be difficult at times but that is part and parcel of working in an agile environment and with so many people putting their hands up for trials, she feels the need to help everyone. 

The pressure to get it right can be immense. Emma and the team are dealing with sensitive issues every day while liaising with staff in hospitals who are on the frontline of the pandemic. But despite this, she can wake up each day knowing that she is doing something meaningful with Spiral, that her job has a purpose and is making a difference in the current world we’re living in. 

“It is easy to get caught up in the emotions of this role but at the same time, it is incredibly rewarding.”

With her one-year anniversary at Spiral just around the corner, Emma feels like she has found herself a role where she can support others to be the best they can be while at the same time, work within a team that ‘keeps it real’ and bands together.

“This really is the dream job. The team spirit and support is amazing- everyone is so genuine and kind - I feel like I've finally found the right role for me and my long term career. I can't imagine doing anything else now.”

Tuesday, June 29, 2021

TTM2 Trial: Hypothermia vs. Normothermia after Out-of-Hospital Cardiac Arrest


A project in Spiral’s study manifest, has recently been used in the long-awaited TTM2 trial. After successful resuscitation, patients who survive a cardiac arrest often remain severely ill and require intensive care. Controlling body temperature is a potential treatment that may prevent brain damage. The TTM2-trial aimed to study the impact on all-cause mortality of targeted hypothermia compared with targeted normothermia.

Monday, May 31, 2021

Meet Jess, one of our Project Leads



Ask her what a typical day or week looks like and Jess can’t help but laugh. 

 “Every day is different and every week throws up new challenges. I find myself to be very busy. The pressures of the pandemic are immense and with the trial being responsive, the build constantly needs to change...you hear of working in an agile environment but this really is as agile as it gets.” 

Monday, March 29, 2021

Spiral donates Chromebooks to help UK students during COVID-19 lockdowns

It’s been over a year since COVID-19 struck the world, and at Spiral we continue to think about the impact it has on our most vulnerable people – and not just in a clinical context. 

With many schools around the world in lockdown, students are expected to learn from home with online lessons. But what happens when a family doesn’t have a device? Or just one device to share between children? 

With this in mind, Spiral recently donated four new HP Chromebooks to Grange First Primary School in the UK. They’re a low decile school in one of the more economically challenged parts of London, and while the government had provided some Chromebooks to assist at-home learning, they were still short. That meant children were having to join lessons from their parent’s phone, or in families with more than one sibling, share devices. This often meant that one or more siblings simply didn’t get to do lessons that day. 





Tuesday, February 23, 2021

Stew Duff, who makes what we do at Spiral technically possible

He’s not a researcher signing up patients for life-saving clinical trials – but he does determine eligibility.

He’s not a doctor, or a nurse, seeing patients and delivering recovery results – but he does do patient follow-ups and reporting. 

He’s not on the front-lines, but he is helping to save lives from the back end.

 Meet Stew, one of our Developers »

Wednesday, February 10, 2021

Application barnacle scraping


Our developers have been engaged in "barnacle scraping" this week. 


Like the hull of a ship, software needs to go through periodic barnacle scraping, especially when we are making lots of changes and adaptations. Adapting our software platform for COVID research studies has pretty much become the norm for us. All those adaptations leave "barnacles" or little extras which are extraneous to the functioning of the platform and can slow things down. 

We can do all this while the software application continues to run so carry on as usual.  The changes we have been making will improve performance, speed up response times and make things smoother for you.

Thank you for your comments and feedback. 

 

Friday, January 01, 2021

Happy New Year 2021

 


This past year has been one for the record books! We just want to say how grateful we are for your support and we’re wishing you all the best as we enter a brand new year.

Head on over to our blog to find out what we are up to »

Tuesday, December 22, 2020

2020 Recap & Merry Xmas


2020 was a year of challenges, to say the least Covid-19 brought immense challenges to everyone in 2020, and it brought us our greatest challenge ever: adapting our Spinnaker platform to manage the world’s most complex clinical trial – a trial that tackled Covid-19 head-on.

A recap of REMAP-CAP: the clinical trial fighting Covid-19

As we speak the REMAP-CAP trial has over 3,500 patients enrolled, in over 15 countries, at 300 sites around the world. And during the year, our software randomised over 5,200 patients – go you awesome researchers! I want to take a moment to reflect on the real human impact. It’s easy to get caught up in technical details and statistics, but at the bottom line, the goal of the REMAP-CAP trial, and the Spinnaker platform, is to try and help real people who are sick – in some cases very sick – have a higher probability of receiving a treatment that will help. We feel proud to have been a part of a study with real-world, immediate impact.

REMAP-CAP milestones 

By February, we were already in the thick of adapting our Spinnaker platform to tackle Covid-19. It’s strange to look back to this article in Stuff in March about our work and read that we had just 50 Covid-19 patients enrolled in the clinical trial to investigate the best treatments. By April, our sprint out of the blocks had become a long-distance run, and we settled in for a marathon effort. Even now, in December, as we prepare data for analysis that will hopefully answer questions about COVID-19 treatment in critically ill patients, the finish line seems far away. But this year hasn’t all been about REMAP-CAP! Here’s a look at some of the other studies we’re excited to be a part of.

Updates on studies using Spinnaker »

News about the Spiral team – we’re growing, fast

An increased demand for our services has resulted in a doubling of the team at Spiral, and we’re so happy to have the new hands on deck for what looks like a busy year ahead. During the year, new team members Jess, Emma and Stew all worked on delivering our Spinnaker trial platform along with Cain, Craig and Anna. Jess also delivered... a new baby! The team at Spiral are distributed across New Zealand, and everyone was able to work from home during our lockdown. The only significant effect of the New Zealand lockdowns was to give us more hours in which to work! But it’s not all work for the team and in August, with travel restrictions lifted, we were able to meet up in Wellington for a few days of eating, working and having fun together.

Community Support

We are grateful for the organisations the help make our communities better places and we showed our appreciation by supporting:
  • Innovative Young Minds. A nation-wide programme encouraging young women in STEMM careers.
  • Books in Homes, Xmas Parcels and Reading Assistance in local schools
  • Wikipedia Foundation.
  • Wellington Free Ambulance.

Take care and enjoy this time with your friends and loved ones. Nga kirihimete, god Jul, Merry Christmas, from Audrey and all the team at Spiral

Friday, September 11, 2020

Meet Jess and Emma our Project Managers

 



Two smart, focussed project managers have joined Spiral recently. It’s very nice to have extra hands on deck to help deliver our Covid-19 projects.

Meet Jess and Emma our Project Managers for REMAP-CAP and for ASCOT-ADAPT.  You can read more about them over on our blog »

Thursday, February 20, 2020

Coronavirus and how we play the adaptation game

We are busy adapting one of our biggest projects to collect data and eventually provide feedback on the best treatment for the novel coronavirus outbreak COVID-19.
Coronavirus mutated( or adapted) recently to give us SARS-CoV-2 and the COVID-19 disease. Adaptation is a great skill for a virus – it's a pretty keen skill for people too, and we are using it to fight back against this disease ... read how »

Tuesday, February 11, 2020

The largest ever cardiac arrest trial performed in an ICU setting uses Spinnaker in novel ways!

January 2020 saw the last patient enrolled in the TTM2 Trial. Congratulations TTM2 – the largest ever cardiac arrest trial performed in an ICU setting!
The trial has been using our Spinnaker Platform in a novel way, which is what this post is about!

Back in 2017 we were approached by Principle Investigator, Niklas Nielsen, looking for a way to streamline the collection of data for TTM2 and a similar study, TAME.  The 2 studies had very similar data points to collect and there seemed to be an opportunity to save time by collecting data just once and sharing it across both studies. Very quickly it got more complicated than that. Patients could be randomised to TTM2, or TAME, or to participate in both studies. The big question was – could the Spinnaker Platform be adapted to this novel design?

We are very proud of our adaptability so we had a close look at what we could do ... follow the story on our blog »

Friday, December 20, 2019

Thanks for your support & have a great Xmas


Silly hats, Pavlova and sand between the toes - it’s that time of year again!
Merry Christmas from all of us at Spiral.

Thanks for your support - Spinnaker was used to randomise over 4,700 patients in 2019!

We are on holiday from the 21st of December and back on the 21st of January. You can check out our holiday hours over on our website »

Tuesday, September 24, 2019

Queenstown 2019 winner


The competition we ran for an iPad at the ANZICS-CTG WRF in Queenstown was very popular! Here are our top 3 and a worthy mention.

Our winning picture with the boat had the accompanying caption: Smooth sailing like #Spinnakersoftware #ANZICSCTG

See all 4 photos and captions via our blogpost »